As I mentioned in the straw about the CellPryme-M platform, I'm looking to see if this new program is causing an increase in costs like @GazD suggested.
Their most recent 4C actually had a pretty big decrease in operating cash flow: -$1,167,000 (June) vs -$1,633,000 (March), which is largely driven by a reduction in R&D costs: $493,000 (June) vs $1,072,000 (March). Their prior 4C (December 2021) had R&D in the middle $827,000, and September 2021 was roughly the same.
In the most recent 4C, on the topic of CellPryme-M they say that ``This program has been in development for some time in stealth mode whilst data was generated and patents filed.'' and so maybe the higher R&D spends in the previous quarters accounted for that.
The takeaway: so far it looks like the CellPryme-M platform isn't leading to increased costs. Of course, a significant reduction in R&D spending by a biotech is an interesting fact by itself, since that's basically their entire business. So I'll be watching to see what happens there.
(Disc: held)